Investing

Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials Cardiol Therapeutics Inc. (NASDAQ: